Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Klein, Oliver

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. [electronic resource] - Cancer immunology, immunotherapy : CII Apr 2015 - 507-18 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

1432-0851

10.1007/s00262-015-1656-x doi


Adult
Aged
Aged, 80 and over
Antigens, Neoplasm--immunology
Antineoplastic Agents, Alkylating--administration & dosage
CD4-Positive T-Lymphocytes--immunology
Cancer Vaccines--administration & dosage
Cholesterol--immunology
Cohort Studies
Combined Modality Therapy
Cyclophosphamide--administration & dosage
Dose-Response Relationship, Drug
Drug Combinations
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Melanoma--immunology
Membrane Proteins--immunology
Middle Aged
Neoplasm Staging
Phospholipids--immunology
Prognosis
Saponins--immunology
T-Lymphocytes, Regulatory--immunology